ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Vertex names chief medical officer Reshma Kewalramani as new CEO

by Lisa M. Jarvis
August 2, 2019 | APPEARED IN VOLUME 97, ISSUE 31

 

09731-buscon16-reshmacxd.jpg
Credit: Vertex Pharmaceuticals
Reshma Kewalramani

Next year will bring a changing of the guard at Vertex Pharmaceuticals. In April 2020, Jeffrey Leiden will step down as CEO and become executive chairman of the board of directors. Leiden became CEO in 2012 and led the Boston-based biotech company through the launch and expansion of its lucrative cystic fibrosis drug franchise. Chief Medical Officer Reshma Kewalramani, who joined Vertex in 2017 after more than 12 years at the biotech firm Amgen, will become the next CEO. Kewalramani will be the first woman to lead a top-five biotech firm.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment